Risk factors for recurrence of common bile duct stones after surgical treatment and effect of ursodeoxycholic acid intervention

doi:10.4240/wjgs.v16.i1.103

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1242)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

WORD

HTML

505

Figures (1-1)

Tables (1-6)

Sum=734

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

175

Sum=268

Publishing Process of This Article

Item

Count

Browse

Download

131

Sum=188

Jan 27, 2024 (publication date) through May 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Jan 27, 2024; 16(1): 103-112
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.103

Table 1 Patient characteristics

Variable		Total (n = 100)	Control (n = 47)	UDCA (n = 53)
Age (yr), median (P₂₅, P₇₅)		53.00 (48, 60)	51 (47, 60)	54 (48.5, 60)
Gender, n (%)	Male	44 (44)	21 (44.68)	23 (23.40)
	Female	56 (56)	26 (55.32)	30 (56.60)
Jaundice, n (%)	Yes	27 (27)	12 (25.53)	15 (28.30)
	No	73 (73)	35 (74.47)	38 (71.70)
Hypertension, n (%)	Yes	25 (25)	12 (25.53)	14 (26.42)
	No	75 (75)	35 (74.47)	39 (73.58)
Diabetes, n (%)	Yes	32 (32)	14 (29.79)	18 (33.96)
	No	68 (68)	33 (70.21)	35 (66.04)
History of biliary tract surgery, n (%)	Yes	14 (14)	6 (12.77)	8 (15.09)
	No	86 (86)	41 (87.23)	45 (84.91)
Parapillary diverticulum, n (%)	Yes	36 (36)	23 (48.94)	13 (24.53)
	No	64 (64)	24 (51.06)	40 (75.47)
No. of stones, n (%)	≤ 3	49 (49)	25 (53.19)	24 (45.28)
	> 3	51 (51)	22 (46.81)	29 (54.72)
Bile culture positive, n (%)		37 (37)	20 (42.55)	17 (32.08)
Common bile duct diameter (mm), median (P₂₅, P₇₅)		14.00 (13.00, 16.00)	15.0 (13.0, 16.0)	14.0 (12.0, 16.0)
Maximum stone diameter (mm), median (P₂₅, P₇₅)		13.00 (12.00, 15.00)	13.0 (12.0, 15.0)	13.0 (11.5, 14.5)
ERCP time (min), median (P₂₅, P₇₅)		64.00 (61.00, 68.00)	63 (61, 67)	64 (61, 71)
WBC (10⁹/L, mean ± SD)		6.60 ± 0.96	6.24 ± 1.24	6.60 ± 0.97
PCT (ng/mL), median (P₂₅, P₇₅)		0.18 (0.12, 0.27)	0.17 (0.12, 0.25)	0.18 (0.13, 0.28)

UDCA: Ursodeoxycholic acid; ERCP: Endoscopic retro-grade cholangiopancreatography; WBC: White blood cell; PCT: Procalcitonin.

Table 2 Comparison of clinical efficacy between control and ursodeoxycholic acid groups

Group	Efficacious	Effective	Ineffective	χ² value	P value
Control, n (%)	16 (34.04)	21 (44.68)	10 (21.28)	3.990	0.048
UDCA, n (%)	22 (41.51)	27 (50.94)	4 (7.55)

UDCA: Ursodeoxycholic acid.

Table 3 Comparison of liver function indexes between control and ursodeoxycholic acid groups

Group	n	TBiL (μmon/L, mean ± SD)		DBiL (μmon/L, mean ± SD)		GGT (U/L, mean ± SD)
Group	n	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
Control	47	96.65 ± 11.24	77.31 ± 8.52	63.74 ± 7.45	45.39 ± 5.69	328.65 ± 20.45	189.63 ± 16.87
UDCA	53	98.63 ± 11.42	55.39 ± 6.53	63.36 ± 7.96	32.10 ± 4.62	330.25 ± 20.64	142.32 ± 14.21
t value		0.872	-14.532	-0.251	-12.896	0.388	-15.217
P value		0.385	< 0.001	0.803	< 0.001	0.699	< 0.001
		ALT (U/L, mean ± SD)		ALP (U/L, mean ± SD)		AST (U/L, mean ± SD)
		Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
Control	47	274.63 ± 25.41	149.36 ± 15.36	256.66 ± 24.12	171.33 ± 22.09	201.32 ± 16.35	121.35 ± 11.57
UDCA	53	268.54 ± 21.23	112.52 ± 14.25	262.36 ± 25.78	122.61 ± 16.00	201.11 ± 15.47	96.98 ± 10.44
t value		-1.306	-12.440	1.139	-12.733	-0.066	-11.072
P value		0.195	< 0.001	0.257	< 0.001	0.947	< 0.001

TBiL: Total bilirubin; DBiL: Direct bilirubin; GGT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; UDCA: Ursodeoxycholic acid.

Table 4 Univariate analysis of recurrence of common bile duct stones after endoscopic retro-grade cholangiopancreatography

Variables		Non-recurrent group (n = 72)	Recurrent group (n = 28)	χ² value	P value
Age (yr, mean ± SD)		54.64 ± 6.62	51.43 ± 8.74	-1.983	0.050
Gender, n (%)	Male	31 (43.06)	13 (46.43)	0.093	0.760
	Female	41 (56.94)	15 (53.57)
Jaundice, n (%)	Yes	19 (26.39)	8 (28.57)	0.049	0.825
	No	53 (73.61)	20 (71.43)
Hypertension, n (%)	Yes	18 (25.00)	8 (28.57)	0.134	0.715
	No	54 (75.00)	20 (71.43)
Diabetes, n (%)	Yes	27 (37.50)	5 (17.86)	3.575	0.059
	No	45 (62.50)	23 (82.14)
History of biliary tract surgery, n (%)	Yes	12 (16.67)	2 (7.14)	1.519	0.218
	No	60 (83.33)	26 (92.86)
Parapillary diverticulum, n (%)	Yes	18 (25.00)	18 (64.29)	13.504	< 0.001
	No	54 (75.00)	10 (35.71)
No. of stones, n (%)	≤ 3	46 (63.89)	11 (39.29)	4.979	0.026
	> 3	26 (36.11)	17 (60.71)
Bile culture positive, n (%)		19 (26.39)	18 (64.29)	12.421	< 0.001
Postoperative treatment, n (%)	Control	26 (36.11)	21 (75.00)	12.240	< 0.001
	UDCA	46 (63.89)	7 (25.00)
Common bile duct diameter(mm), median (P₂₅, P₇₅)		14.00 (12.00, 15.00)	16.00 (14.00, 17.00)	-3.265	0.001
Maximum stone diameter(mm), median (P₂₅, P₇₅)		12.00 (11.25, 13.75)	15.00 (12.00, 16.00)	-3.599	< 0.001
ERCP time (min, mean ± SD)		63.93 ± 5.12	65.82 ± 5.33	1.640	0.140
WBC (× 10⁹/L, mean ± SD)		6.45 ± 1.05	6.38 ± 1.27	-0.290	0.772
PCT (ng/mL), median (P₂₅, P₇₅)		0.18 (0.12, 0.27)	0.18 (0.12, 0.28)	-0.088	0.930
TBiL (μmon/L, mean ± SD)		97.85 ± 10.95	97.32 ± 12.43	-0.211	0.833
DBiL (μmon/L, mean ± SD)		64.13 ± 7.64	62.02 ± 7.76	-1.234	0.220
GGT (U/L, mean ± SD)		330.90 ± 19.82	325.88 ± 21.99	-1.102	0.273
ALT (U/L, mean ± SD)		272.31 ± 22.87	269.09 ± 24.88	-0.617	0.538
ALP (U/L, mean ± SD)		259.81 ± 25.79	259.36 ± 23.50	-0.079	0.937
AST (U/L, mean ± SD)		201.12 ± 16.02	201.44 ± 15.55	0.089	0.929

ERCP: Endoscopic retro-grade cholangiopancreatography; UDCA: Ursodeoxycholic acid; WBC: White blood cell; PCT: Procalcitonin; TBiL: Total bilirubin; DBiL: Direct bilirubin; GGT: Gamma-glutamyl transferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase.

Table 5 Variable assignment description

Variables	Assignment
Parapillary diverticulum	0 = no, 1 = yes
No. of stones	0 = ≤ 2, 1 = > 3
Bile culture positive	0 = no, 1 = yes
Postoperative treatment	0 = UDCA, 1 = control
Common bile duct diameter	Original value
Maximum stone diameter	Original value

UDCA: Ursodeoxycholic acid.

Table 6 Multivariate logistic regression analysis comparing the non-recurrent group vs recurrent groups

Variables	β	SE	Wald χ²	P value	OR (95%CI)
Parapillary diverticulum	1.792	0.646	7.692	0.006	6.003 (1.692-21.303)
No. of stones > 3	1.443	0.654	4.863	0.027	4.233 (1.174-15.263)
Bile culture positive	2.029	0.663	9.357	0.002	47.606 (2.073-27.910)
Postoperative UDCA	-1.287	0.628	4.199	0.040	0.072 (0.080-0.094)
Maximum stone diameter	0.527	0.265	3.957	0.047	1.694 (1.008-2.847)
Constant	-8.895	2.360	14.211	< 0.001	-

UDCA: Ursodeoxycholic acid.

Citation: Yuan WH, Zhang Z, Pan Q, Mao BN, Yuan T. Risk factors for recurrence of common bile duct stones after surgical treatment and effect of ursodeoxycholic acid intervention. World J Gastrointest Surg 2024; 16(1): 103-112
URL: https://www.wjgnet.com/1948-9366/full/v16/i1/103.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i1.103